International Journal of Pharmaceutical Investigation logo
Submit
International Journal of Pharmaceutical InvestigationACADEMIC PUBLISHING
Review

Nanoscale Formulations for Targeted Drug Delivery: Enhancing Stability, Release Control and Therapeutic Efficacy

1, 1★, 2, 3, 4, 1, 1★ Corresponding author

  1. 1Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Saveetha Nagar, Chennai, Tamil Nadu, INDIA.
  2. 2Assistant Professor, Department of Pharmaceutics, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, INDIA.
  3. 3Manager Analytical Chemistry, Elixir Medical Corporation, 920 N McCarthy Blvd #100, Milpitas, CA 95035, UNITED STATES.
  4. 4Research Scholar, Department of Pharmaceutics, Raffles University, Neemrana, Alwar, Rajasthan, INDIA.

CORRESPONDENCE

Ramaiyan Velmurugan

Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Saveetha Nagar, Chennai, Tamil Nadu, INDIA.

velmuruganr.scop@saveetha.com

Received: 17-11-2024; Revised: 23-01-2024; Accepted: 07-03-2025.

Volume 15, Issue 3 · pp. 837-848 · 2025 · DOI: 10.5530/ijpi.20250189

ABSTRACT

The present study focuses on the nanoscale formulation technique for pharmacological agent delivery, avoiding the shortcomings of conventional protocols, such as rapid pharmaceutical clearance, limited site-specific accuracy and reduced biological accessibility. The goal of this is that because nanoscale particles can improve stability, control pharmaceutical release and increase penetration, they have emerged as a promising drug delivery technology. Targeted therapies for conditions like septicemia and bronchial asthma can be developed by attaching particular molecular binders to nanoscale particles. This reduces toxicity while maximizing therapeutic efficacy. In summary, this analysis highlights the medicinal delivery potential of nanoscale formulations, including the mechanisms of action of botanical constituents such as flavonoids and triterpenoidal compounds. It also implies that the administration of inflammatory conditions may benefit greatly from the use of nanoscale particles loaded with these compounds.

KEYWORDS

0% READ

FULL TEXT

INTRODUCTION

Defending against harmful stimuli like allergens or damaged tissues, inflammatory responses can also result from uncontrollably responding to a range of illnesses, including infections from bacteria, metabolic diseases, cardiac abnormalities and malignant tumours; it is illustrated in (Figure 1). These conditions have a significant financial burden on social systems (Tables 1 and 2). While there are many different therapeutic options to reduce inflammation, such as corticosteroids, non-corticosteroids and immunomodulatory drugs, they are frequently harmful when taken at the higher dosages needed to achieve therapeutic plasma concentrations (Ghasemian et al., 2016; Bagad et al., 2013; López et al., 2021). Therefore, investigating phytogenic treatments is essential to overcome the drawbacks of synthetic pharmaceuticals. Highly valued for their taste, scent, or medicinal properties, botanical substances have been utilized to treat a range of illnesses and metabolic issues in addition to lowering inflammation and neutralizing reactive oxygen species. The purpose of this review is to assess botanical ingredients’ ability to reduce inflammation in a variety of disorders, emphasizing their benefits over traditional treatment approaches and investigating their potential as effective substitutes for treating inflammatory diseases.

Drug Delivery Systems

The efficiency of flavonoids as anti-inflammatory agents and their bioavailability have been greatly increased by the application of nanotechnology. Nanoscale particles, such as polylactic acid, Poly (Lactic-Co-Glycolic Acid) (PLGA) and polyoxymethylene glycol, are commonly utilized for phytochemical component transfer and pharmacokinetic parameter modification. For example, it has been shown that polyoxymethylene glycol nanoscale particles increase quercetin's stability, solubilization and circulation persistence in the vascular system (Wang et al., 2013). Many morbidities, including high blood sugar levels, elevated blood pressure, infections of the upper respiratory tract, pancreatic and mammary carcinomas and heart abnormalities, have been linked to quercetin's possible therapeutic advantages (Bennet et al., 2012; Yu et al., 2007; Kumari et al., 2012; Cunico et al., 2020; Bose and Michniak, 2013; Li et al., 2009). However, its poor clinical relevance and efficacy are caused by low intrinsic bioactivity (<10%), considerable metabolic degradation (>40%), fast physiological elimination (<1 hr), limited hydro solubility (1 μg/mL) and inactive substances.

To get around these challenges, a variety of delivery modalities have been developed, including inclusion complexes and micelles, phospholipid vesicles, inorganic nanoscale particulates, polymeric nanoscale particulates/microspheres and other nanomaterials. Pentacyclic triterpenoidal substances have not been utilized in medicine despite having advantageous properties, Thus, the efficacy of in vivo therapy is not always correlated with its biological consequences (Kaps et al., 2021; Ghante and Jamkhande, 2019; Szakiel et al., 2012; Xia et al., 2017; Yu et al., 2020; Shao et al., 2020; Patra et al., 2018). Figure 2 presents an overview of the general benefits of Drug Delivery Mechanisms (DDMs).

Nano Drug Delivery Systems

Numerous research investigations have been carried out to determine which botanical compounds and entities from dietary and medicinal flora are effective for treating a variety of clinical disorders. On the other hand, rapid metabolism, limited permeability and instability can all hinder the bio utilization of such herbal bioactive substances, which is essential to their effectiveness (Yadav et al., 2011). In order to overcome the drawbacks of conventional therapy, nanoscale pharmaceutical delivery has become a viable method for delivering active ingredients. Pharmacological researchers have taken notice of the special qualities of nano vehicles, such as their increased surface area, quick evacuation from the stomach, controlled delivery to specific sites, increased internalization of cells, better bio utilization and biodistribution, affordability, patient compliance and increased healing efficacy (Yetisgin et al., 2020).

Solid Lipid Nanovesicles (SLNs), nanoscale lipid-based entities, have attracted considerable interest worldwide despite the absence of polymeric materials with regulatory approval and their exorbitant price. The stiff core lipid matrix of SLNs provides increased stability of active principles, one of the many benefits they have over liposomal entities (Mishra et al., 2018). SLNs also demonstrate improved entrapment efficiency, regulated release for lipophilic drugs and appropriate modification for targeted therapeutics (Satapathy et al., 2021). Additionally, SLNs are superior to polymeric nanovesicles in that they can be produced on a large scale, are more stable and do not require organic solvents (Rizvi et al., 2019). Many studies have revealed advantageous phytochemical entities from medicinal and dietary flora that can treat a range of pathological disorders. One possible way to improve the distribution of active principles while addressing these issues is through nanoscale pharmaceutical delivery.

Pharmacologists have been drawn to nano vehicles because of their intriguing properties, which include enhanced pharmacokinetics, precise targeting and reduced cytotoxicity. Because of their superior toughness, improved encapsulation efficiency and mass-production feasibility, Lipid-Based Nano Capsules (LNCs) have become the preferred option over polymeric nano capsules. To be more precise, LNCs are very histocompatible since they are made of endogenous and biodegradable lipids; they are more robust because of their stiff lipid core; and they are made with less effort because they don't require complicated polymeric structures during the manufacturing process. In addition, LNCs are more histocompatible than polymeric nano capsules and may be customized for precision therapies, which makes them a desirable choice for effective phytochemical drug administration (Rawat et al., 2023; Sharma et al., 2019).

Challenges in Formulating Nano Formulations

Nanoscale entities with customized architecture, size and dispersal can often be produced by adjusting fabrication processes, reductive catalysts and stabilizing agents (Roy et al., 2019). Due to variations in the phytochemical extracts used, the morphology and dimensions of the nanoscale entities are significantly influenced by them. Consequently, standardizing and producing nanoscale objects with the necessary size, topology and surface characteristics requires optimization of the manufacturing paradigm (Patil and Chandrasekaran, 2020). Although state-of-the-art nanoscale formulations for drug delivery systems are constantly being developed and provide several advantages, there are still some barriers that keep them from being widely deployed. Researchers have challenges while developing and manufacturing nanoscale formulations due to a variety of factors, such as (i) biomaterial characteristics; (ii) fabrication restrictions; (iii) payload capability; (iv) stability; and (v) biological hurdles (Yetisgin et al., 2020; Shao et al., 2020).

The characteristics of biomaterials, such as their biodegradability or surface moiety charge, can affect their membrane permeability, cytotoxicity and biocompatibility (Santos et al., 2019). Producing consistent product batches free of unwanted fabrication byproducts requires an effective and scalable production strategy for nanoscale formulations (Kahraman et al., 2017).

Pharmacokinetics of Nano Formulations

Distinct delivery systems allow Nano Formulations to be introduced into the body and precisely target particular body locations. Nanoparticle characteristics including size, concentration, surface electronegativity and hydrogen ion concentration have a significant influence on pharmacokinetic processes, such as absorption and dissolution. A rise in the bloodstream's level of nanoparticles during a single day that is dose-dependent has been demonstrated by empirical evidence, with the liver, kidney and lungs exhibiting the most significant accumulation over a 72-hr period. The results emphasize the significant impact of nanoparticle properties on pharmacokinetic mechanisms and possible toxicity, indicating that urine excretion is the main method of eliminating tiny nanoparticles, while feces and the biliary system are the main routes of elimination for bigger ones. The quantity of nanoparticles in circulation rises dose-dependently and is linked to increasing toxicity; the organs most impacted are the liver and splenic ones.

To minimize potential negative effects, it is imperative to customize the size and concentration of nanoparticles according to the the area of the target and the degree of inflammation. Moreover, surface modification using Ethylene Diamine Tetra Methylene Phosphonic Acid (EDTMP) has been shown to lessen the cytotoxicity of nanoparticles by lessening the oxidative stress that is caused by high nanoparticle concentrations (Imperiale et al., 2019; Chen et al., 2017).

Inflammation

In response to external stimuli, the immune system produces inflammation as a defense mechanism in response to things like pathogen invasions, cellular destruction, toxic substances, or ionizing radiation (Medzhitov, 2010; Ferrero et al., 2007; Nathan and Ding, 2010; Zhou et al., 2016). Usually, this defensive reaction restores tissue homeostasis and reduces inflammation by reducing the likelihood of infection or trauma through cellular and molecular processes. Leukocyte mobilization, pro-inflammatory mediator release and altered vascular permeability are all significant outcomes of this process (Chertov et al., 2000). Irritation manifests as irritation, edema, heat, discomfort and tissue dysfunction because of localized inflamed, vascular and immune cell reactions to injury or infection (Takeuchi et al., 2010). An array of factors, mostly pertaining to the upper respiratory tract and nasal cavities, can cause inflammation, such as pathogenic invasions, severe temperature swings, toxic chemicals, physical trauma and abnormalities in health.

A defective multi systemic response to airway stimulation, including effector cells and pro-inflammatory mediators, is the hallmark of asthma, a chronic inflammatory airway illness. Sepsis, on the other hand, is a potentially fatal reaction to pathogenic invasion that releases pro-inflammatory mediators and damages numerous organs. Individuals may have symptoms like hypotension, pyrexia, decreased urine production, impaired hemostasis, increased vascular permeability and loss of smooth muscle tone. These illnesses have been treated with synthetic medications such as corticosteroids, leukotriene receptor antagonists and antimicrobials (Yatoo et al., 2018; Jamtsho et al., 2024; Bjorkman, 1998; Ricciotti and FitzGerald, 2011; Rainsford, et al., 2007; Bermas, et al., 2014; Shaikh et al., 2012; Juthani et al., 2017; Moskovtchenko and Cognet, 1976; Ayroldi et al., 2012; Celotti and Laufer, 2001).

These pharmacological categories, although therapeutically beneficial, are also associated with a wide range of adverse reactions, such as fever, gastrointestinal distress, nasal blockage, aural infections, cutaneous manifestations, pruritic eruptions, bronchial irritation, tussive episodes, sinusoidal infections, upper respiratory tract disorders, atopic eczema, cranial discomfort, nausea, laryngeal inflammation, pharyngeal inflammation, viral afflictions, dyspneic episodes, odontalgic pain, vertiginous sensations, gastric dyspepsia and increased levels of hepatocellular enzymes. In contrast, a number of plant components (including flavonoids and triterpenoids) found in phytotherapeutic treatments have been demonstrated to improve immunological response and offer numerous other advantages, which helps to mitigate the drawbacks of traditional treatment approaches (Altavilla et al., 2009; Lin et al., 2008; Aggarwal et al., 2011). Figure 3 illustrates the mechanistic effects of different coactivational substances and receptors.

In the cytosol, where the Rel and p50 proteins are found, NF-κβ forms a complex with the inhibitory protein Iκβα when it is in its active state. Membrane receptors pick up extracellular signals, which then activate Iκb Kinase (IKK). The IKK then phosphorylates the Iκβα protein, which causes it to get ubiquitinated and eventually be degraded by the proteasome (by the canonical pathway). RelB prefers the non-canonical NF-κβ activation route through RelB. Response Elements (RE) are DNA bindings that induce NF-κβ to translocate into the nucleus and bind. Coactivators and RNA polymerase are drawn to the DNA/NF-κβ complex, which causes the latter to produce mRNA from the DNA and change the cell.

Function of Triterpenoids and Flavonoids in Inflammation

Due to differences in their chemical structures, flavonoids may be divided into six groups: flavones, phenols, flavanonols, isoflavonoids, flavan-3-ols and anthocyanins, are found in a wide range of plant materials, such as fruits, flowers and leaves (Choy et al., 2019; Pollastri and Tattini, 2011; Barreca et al., 2017). Studies have indicated that in the presence of chronic inflammation, triterpenoids and flavonoids impact several redox pathways, including Nuclear Factor kappa B (NFκB). The transcriptional regulation NFκB is activated by inflammatory stimuli, leading to the suppression of the Inhibiting kappa B (IκB) kinase. This finally results in cellular death and a rise in pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α). It has been observed that flavonoids and triterpenoids reduce oxidative stress in a variety of medical conditions, as well as the concentrations Elevated blood serum levels of TNF-α or Interleukin-1 beta (IL-1β), as well as blood mononuclear cells' NFκB transcriptional activity (Chekalina et al., 2018; Indra et al., 2013; Tang et al., 2014; Oyagbemi et al., 2018; Lv et al., 2011; Garg et al., 2019; Ren et al., 2018; Xiong et al., 2018; Lee et al., 2012; Rani et al., 2016; Han et al., 2015; Suchal et al., 2016; Kashyap et al., 2016).

Referring to Figure 5, Figure 4 depicts the inflammatory mechanism. Diverse treatment methods, such as corticosteroidal and non-corticosteroidal ones, are being continually investigated to manage acute inflammatory responses. Unfortunately, these techniques frequently fall short of the intended therapeutic result because of drawbacks including non-specific pharmacokinetic distribution, limited bioavailability, or short half-lives, which force doctors to prescribe higher dosages and cause unintended side effects. Nanoscale particles are becoming more and more popular as a solution to these problems because of their ability to target specific molecular entities, minimize toxicity and negative effects and facilitate controlled release in affected cellular and tissue structures. They also have controlled dimensions, morphology and surface charge.

Nanoscale formulations demonstrate a significant advantage in regulating maintaining the proper ratio of pro-to-anti-inflammatory effectors and using endocytic absorption to target cell phagocytic or inflammatory sentinels in particular. In addition, precision targeting of particular cell populations with nanovehicular systems might greatly improve immune response or intracellular internalization to suppress inflammation. Anti-inflammatory nanopharmaceuticals are the product of significant efforts to develop anti-inflammatory tactics that overcome the constraints of conventional pharmaceutical forms (Maio et al., 2021; Cai et al., 2021; Jubilee et al., 2024; Costanzo et al., 2016).

Table 1: The way that different flavanoids and triterpenoids affect inflammation.
Sl. No.PhytoconstituentsPlant sourceActive compoundMechanism of actionReferences
1FlavanoidSambucus canadensis L., Ginkgo biloba L. and Hypericum perforatum L.QuercetinSuppression of cyclooxygenase 2 blocking AP-1’s attachment the leptin receptor, to extracellular signal-regulated kinase Ob-Ra and Mitogen-Activated Protein Kinase (MAPK) K/p38 kinase.(Mirza et al., 2023; Kwak et al., 2016; Shabir et al., 2022; Li et al., 2016; Serafini et al., 2010; Ferraz et al.,2020; Cunha et al., 2010; Sachs et al., 2004; Ntalouka and Tsirivako, 2023; Choy et al., 2019; Krishna et al., 2024).
2FlavanoidsSalvadora persicaLuteolin-8 CfucopyraNOSide (LU8C-FP).Decrease in IL-6.(Lv et al., 2011; Aziz et al., 2018).
3FlavnoidsRuta graveolensRutinBoth Nuclear factor E2-related factor (Nrf) stimulation and Nuclear factor (NF-κB) repression are involved.(Álvarez et al., 2016; Ganeshpurkar et al., 2017; Rauf et al., 2017;Farzaei et al., 2019).
4FlavanoidsReseda luteola LLuteolinNF-κB, TNF-α and IL-6 reduction inhibition.(Arampatzis et al., 2023; Al-Khayri et al.,2022; Choy et al., 2019; Muruganathan et al., 2022).
5FlavanoidsSumach from Venice (Rhus cotinus L.)FisetinReduced levels of Tumor Necrosis Factor (TNF-α), Interleukin (IL-1β and IL-8).(Grynkiewicz and Demchuk, 2019; Grynkiewicz and Demchuk, 2019; Choy et al., 2019; Garg et al., 2019).
6TriterpenoidsSouroubeasympetalaBetulinic acidBy modulating the NF-kB pathway, betulinic acid reduces the generation of IL-6 and inhibits the formation of nitric oxide.(Puniani et al., 2014; Jeong et al., 2009; Lin et al., 2015; Yun et al., 2003).
7TriterpenoidsLisgustrum lucidumOleanolic acidBlocking Liposaccharide (LPS) release, which is a mediator of the synthesis of Cell Adhesion Molecules (CAMs) and High Mobility Group Box 1 (HMGB1).(VYAS et al., 2014; Xia et al., 2011; Yang et al., 2012; Andersson et al., 2011; Lee et al., 2013).
8TriterpenoidsHerbs (such as organum, marjoram, rosemary, lavender and thyme), fruits (such as apple peel) and flowers. Australian sambucus.Ursolic acidLower the quantities of IL-1β, IL-6, IL-8 and TNF-α, which are indicators of inflammation.(Woźniak et al., 2015; Jäger et al., 2009; Szakiel et al., 2012; Zhao et al., 2023).
9TriterpenoidsAmericans' ginseng Sebastianiaadenophora, Crataevanurvala, Bombax ceiba, Leptadeniahastata, Hematanthussucuuba, Shea butter plant species include andriedelianum.Lupeol acidModifying the mRNA unique to IL-2 and TNF-alpha.(Saleem, 2009; Beveridge et al., 2002; Fernández et al., 2001; Vasconcelos et al., 2008; Yamashita et al., 2002; Lucetti et al., 2010).
10TriterpenoidsCentella asiaticaAsiatic acidControl of NOS, IL-1β, COX-2 and IL-6.(Nagoor et al., 2018; Kamble et al., 2017; Patil et al., 2015; Yang et al., 2018).
11TriterpenoidsOlea europaeaMaslinic acidPreventing the synthesis of Tumour Necrosis Factor alpha (TNF-α) and nitric oxide.(Lozano et al., 2014; Ooi et al., 2023; Lu et al., 2009; Banno et al., 2005; Kim et al., 2005; Huang et al., 2011).
12TriterpenoidsPlanta odorum, Nerium oleanderOleandrinReduced Phosphatidylinositol 3-Kinase (PI3K), phosphorylated Ak strain transforming (Akt) and inhibition of NF-κB.(Zhai et al., 2022; Khan et al., 2010; Atay et al., 2018).
Table 2: Reports of different phytoconstituents in Nanoformulations.
Sl. No.Plant-based compositesNanoformulationActive ingredientInflammation-related illnessReferences
1FlavanoidsPLGA NanoparticlesQuercetinAntimicrobialactivity(Kaps et al., 2021).
2TriterpenoidsGold NanoparticlesBetulinic acidAnticancer disease(Mioc et al., 2018).
3TriterpenoidsPentacyclic triterpenoid - Lupeol Nanoemulsion.LupeolAntimalarial illness(Dwivedi et al., 2023).
4TriterpenoidsLiposomesUrsolic acidAnti malignant tumor action(Sysak et al., 2023).
5TriterpenoidsChitoson Nanodrug Carrier.Ursolic acidAntitumor activity(Shao et al., 2020).
6FlavanoidsSilver Nanoparticles with Quercetin.QuercetinThe anti-inflammatory property.(Wang et al., 2021).
7TriterpenoidsAcid ursolic nanosuspension.Ursolic acidDiabetes type 2(Nie et al., 2020).
8FlavanoidsParticles of nanoscale Acetate phthalate of cellulose, silica nanoparticles and nanoparticles The polycaprol act one particles of nanoscale Silica nanoparticles, polycaprolactone nanoparticles and cellulose acetate phthalate.QuercetinAnti-rheumaticeffect(Guan et al., 2021).
9FlavanoidsBoth solid lipid and polymer nanoparticles, solid lipid nanoemulsions, elastic liposomes and nanostructured lipid transporters.Quercetin, Rutin and LuteinTopical infectious disorders(Dwivedi et al., 2023; Derman et al., 2020; Viscusi et al., 2023).
10FlavanoidsMetallic oxide, silver and gold nanoparticles.QuercetinViral disease(Jannat et al., 2021).
Figure 1: A graphic representation of the various forms of both acute and chronic inflammation.
Figure 2: Efficacy of Drug Delivery systems.
Figure 3: The method by which NFκB operates.
Figure 4: A number of infections and allergens in the environment cause immune cells to release specific cytokines and chemokines, which chemotactically trigger eosinophil infiltration through endothelial cells at the site of inflammation and intensify the inflammatory process.
Figure 5: Recent nanomedicines for the treatment of inflammation.

CONCLUSION

The treatment of inflammation could be completely transformed by the combination of nanotechnology and herbal products. Improved patient outcomes can be achieved by using Nano Formulations to optimize drug administration, improve biocompatibility and minimize side effects. This strategy offers a viable treatment for chronic inflammatory illnesses while addressing the drawbacks of traditional therapies. Researchers can develop effective and tailored medicines by using Nano Formulations, which will ultimately change the way disease management is handled. Approaches to personalized treatment are made possible by the adaptability of Nano Formulations, which enable targeted moieties and customized designs. To fully achieve the potential of Nano Formulations and make them a reality for patients, more research is required. Nano Formulations have the potential to significantly improve the lives of millions of people globally by serving as a cornerstone of inflammatory control with further innovation. It appears that the therapy of inflammation has a bright future and Nano Formulations will likely be crucial in determining that future. To realize their full potential, ongoing research is essential.

Conflict of Interest

The authors declare that there is no conflict of interest.

Author Contributions

Lokeshvar R: Writing-original draft, Resources, Writing-review and editing. Velmurugan R: Supervision, Conceptualization, Validation. Mahalakshmi Devaraji: Method Validation. Yokesh S, Karthika R, Saran R, Shyam Sundar S: Writing-review and editing.

REFERENCES

As published

Showing references and in-text citations exactly as published.

  1. Aggarwal, B. B, Prasad, S, Reuter, S, Kannappan, R, Yadev, V. R, Park, B, Kim, J. H, Gupta, S. C, Phromnoi, K, Sundaram, C, Prasad, S, Chaturvedi, M. M, & Sung, B. (2011). Identification of novel anti-inflammatory agents from ayurvedic medicine for prevention of chronic diseases: “Reverse pharmacology” and “bedside to bench” approach. Current Drug Targets, 12(11), 1595–1653. https://doi.org/10.2174/138945011798109464CrossrefGOOGLE SCHOLAR
  2. Al-Khayri, J. M, Sahana, G. R, Nagella, P, Joseph, B. V, Alessa, F. M, & Al-Mssallem, M. Q. (2022). Flavonoids as potential anti-inflammatory molecules: A review. Molecules, 27(9), 2901. https://doi.org/10.3390/molecules27092901CrossrefGOOGLE SCHOLAR
  3. Altavilla, D, Squadrito, F, Bitto, A, Polito, F, Burnett, B. P, Stefano, D, V, & Minutoli, L. (2009). Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. British Journal of Pharmacology, 157(8), 1410–1418. https://doi.org/10.1111/j.1476-5381.2009.00322.xCrossrefGOOGLE SCHOLAR
  4. Álvarez, R, Araya, H, Navarro-Lisboa, R, Dicastillo, L. D, & C (2016). Evaluation of polyphenol content and antioxidant capacity of fruits and vegetables using a modified enzymatic extraction. Food Technology and Biotechnology, 54(4), 462–467. https://doi.org/10.17113/ftb.54.04.16.4497CrossrefGOOGLE SCHOLAR
  5. Andersson, U, & Tracey, K. J. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology, 29, 139–162. https://doi.org/10.1146/annurev-immunol-030409-101323CrossrefGOOGLE SCHOLAR
  6. Arampatzis, A. S, Pampori, A, Droutsa, E, Laskari, M, Karakostas, P, Tsalikis, L, Barmpalexis, P, Dordas, C, & Assimopoulou, A. N. (2023). Occurrence of luteolin in the greek flora, isolation of luteolin and its action for the treatment of periodontal diseases. Molecules, 28(23), 7720. https://doi.org/10.3390/molecules28237720CrossrefGOOGLE SCHOLAR
  7. Ayroldi, E, Cannarile, L, Migliorati, G, Nocentini, G, Delfino, D. V, & Riccardi, C. (2012). Mechanisms of the anti-inflammatory effects of glucocorticoids: Genomic and nongenomic interference with MAPK signaling pathways. FASEB Journal, 26(12), 4805–4820. https://doi.org/10.1096/fj.12-216382CrossrefGOOGLE SCHOLAR
  8. Aziz, N, Kim, M, & Cho, J. Y. (2018). Anti-inflammatory effects of luteolin: A review of in vitro, in vivo and in silico studies. Journal of Ethnopharmacology, 225, 342–358. https://doi.org/10.1016/j.jep.2018.05.019CrossrefGOOGLE SCHOLAR
  9. Bagad, A. S, Joseph, J. A, Bhaskaran, N, & Agarwal, A. (2013). Comparative evaluation of anti-inflammatory activity of curcuminoids, turmerones and aqueous extract of curcuma longa. Advances in Pharmacological Sciences, Article 805756. https://doi.org/10.1155/2013/805756CrossrefGOOGLE SCHOLAR
  10. Balkan, A, Gören, A. C, Kırmızıbekmez, H, & Yeşilada, E. Y. (2018). Evaluation of the in vitro anti-inflammatory activity of nerium oleander L. Flower Extracts and Activity-guided Isolation of the Active Constituents. Records of Natural Products, 12(2), 128–141. https://doi.org/10.25135/rnp.15.17.05.100CrossrefGOOGLE SCHOLAR
  11. Banno, N, Akihisa, T, Tokuda, H, Yasukawa, K, Taguchi, Y, Akazawa, H, Ukiya, M, Kimura, Y, Suzuki, T, & Nishino, H. (2005). Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of eriobotrya japonica. Biological and Pharmaceutical Bulletin, 28(10), 1995–1999. https://doi.org/10.1248/bpb.28.1995CrossrefGOOGLE SCHOLAR
  12. Barreca, D, Gattuso, G, Bellocco, E, Calderaro, A, Trombetta, D, Smeriglio, A, Laganà, G, Daglia, M, Meneghini, S, & Nabavi, S. (2017). M. . Flavanones: Citrus Phytochemical With Health-promoting Properties. Bio Factors, 43(4), 495–506. https://doi.org/10.1002/biof.1363CrossrefGOOGLE SCHOLAR
  13. Bennet, D, Marimuthu, M, Kim, S, & An, J. (2012). Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery. International Journal of Nanomedicine, 7, 3399–3419. https://doi.org/10.2147/IJN.S32800CrossrefGOOGLE SCHOLAR
  14. Bermas, B. L. (2014). Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Current Opinion in Rheumatology, 26(3), 334–340. https://doi.org/10.1097/BOR.0000000000000054CrossrefGOOGLE SCHOLAR
  15. Beveridge, T. H. J, Li, T. S. C, & Drover, J. C. G. (2002). Phytosterol content in american ginseng seed oil. Journal of Agricultural and Food Chemistry, 50(4), 744–750. https://doi.org/10.1021/jf010701vCrossrefGOOGLE SCHOLAR
  16. Bjorkman, D. J. (1998). The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. The American Journal of Medicine, 105(1b), 8s-12s. )00069-, 2. https://doi.org/10.1016/s0002-9343(98CrossrefGOOGLE SCHOLAR
  17. Bose, S, & Michniak-Kohn, B. (2013). Preparation and characterization of lipid based nano systems for topical delivery of quercetin. European Journal of Pharmaceutical Sciences, 48(3), 442–452. [EPub]. https://doi.org/10.1016/j.ejps.2012.12.005CrossrefGOOGLE SCHOLAR
  18. Cai, Z, Wang, S, & Li, J. (2021). Treatment of inflammatory bowel disease: A comprehensive review. Frontiers in Medicine, 8, Article 765474. https://doi.org/10.3389/fmed.2021.765474CrossrefGOOGLE SCHOLAR
  19. Celotti, F, & Laufer, S. (2001). Anti-inflammatory drugs: New multitarget compounds to face an old problem. The Dual Inhibition Concept. Pharmacological Research, 43(5), 429–436. https://doi.org/10.1006/phrs.2000.0784CrossrefGOOGLE SCHOLAR
  20. Chekalina, N, Burmak, Y, Petrov, Y, Borisova, Z, Manusha, Y, Kazakov, Y, & Kaidashev, I. (2018). September–October). Quercetin Reduces the Transcriptional Activity of NF-kB in Stable Coronary Artery Disease. Indian Heart Journal, 70(5), 593–597. https://doi.org/10.1016/j.ihj.2018.04.006CrossrefGOOGLE SCHOLAR
  21. Chen, L, Deng, H, Cui, H, Fang, J, Zuo, Z, Deng, J, Li, Y, Wang, X, & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204–7218. https://doi.org/10.18632/oncotarget.23208CrossrefGOOGLE SCHOLAR
  22. Chertov, O, Yang, D, Howard, O. M, & Oppenheim, J. J. (2000). Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunological Reviews, 177, 68–78. https://doi.org/10.1034/j.1600-065x.2000.17702.xCrossrefGOOGLE SCHOLAR
  23. Choy, K. W, Murugan, D, Leong, X, Abas, R, Alias, A, & Mustafa, M. R. (2019). Flavonoids as natural anti-inflammatory agents targeting nuclear factor-kappa B (NFκB) signaling in cardiovascular diseases: A mini review. Frontiers in Pharmacology, 10, 1295. https://doi.org/10.3389/fphar.2019.01295CrossrefGOOGLE SCHOLAR
  24. Costanzo, P, Cariati, L, Desiderio, D, Sgammato, R, Lamberti, A, Arcone, R, Salerno, R, Nardi, M, Masullo, M, & Oliverio, M. (2016). Design, synthesis and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Medicinal Chemistry Letters, 7(5), 470–475. https://doi.org/10.1021/acsmedchemlett.5b00483CrossrefGOOGLE SCHOLAR
  25. Cunha, T. (2010). M, Roman-Campos, D, Lotufo, C. M, Duarte, H. L, Souza, G. R, Verri, W. A, Funez, M. I, Dias, Q. M, Schivo, I. R, Domingues, A. C, Sachs, D, Chiavegatto, S, Teixeira, M. M, Hothersall, J. S, Cruz, J. S, Cunha, F. Q, Ferreira, S. H. Morphine Peripheral Analgesia Depends on Activation of the PI3Kgamma/AKT/nNOS/NO/KATP Signaling Pathway. Proceedings of the National Academy of Sciences of the United States of America, 107(9), 4442–4447. https://doi.org/10.1073/pnas.0914733107CrossrefGOOGLE SCHOLAR
  26. Cunico, L. P, Cobo, A. M, Al-Hamimi, S, & Turner, C. (2020). Solubility and thermal degradation of quercetin in CO2-expanded liquids. Molecules, 25(23), 5582. https://doi.org/10.3390/molecules25235582CrossrefGOOGLE SCHOLAR
  27. Derman, S, Uzunoglu, D, Acar, T, Arasoglu, T, Ucak, S, Ozalp, V. C, & Mansuroglu, B. (2020). Antioxidant activity and hemocompatibility study of quercetin loaded plga nanoparticles. Iranian Journal of Pharmaceutical Research, 19(1), 424–435. https://doi.org/10.22037/ijpr.2020.1101000CrossrefGOOGLE SCHOLAR
  28. Dwivedi, K, & Mandal, A. (2023). K, Afzal, O, Altamimi, A. S. A, Sahoo, A, Alossaimi, M. A, Almalki, W. H, Alzahrani, A, Barkat, M. A, Almeleebia, T. M, Mir Najib Ullah, S. N, Rahman, M. Emergence of Nano-based Formulations for Effective Delivery of Flavonoids Against Topical Infectious Disorders. Gels, 9(8), 671. https://doi.org/10.3390/gels9080671CrossrefGOOGLE SCHOLAR
  29. Farzaei, M. (2019). H, Singh, A. K, Kumar, R, Croley, C. R, Pandey, A. K, Coy-barrera, E, Kumar Patra, J, Das, G, Kerry, R. G, Annunziata, G, Tenore, G. C, Khan, H, Micucci, M, Budriesi, R, Momtaz, S, Nabavi, S. M, Bishayee, A. Targeting Inflammation By Flavonoids: Novel Therapeutic Strategy for Metabolic Disorders. International Journal of Molecular Sciences, 20(19), 4957. https://doi.org/10.3390/ijms20194957CrossrefGOOGLE SCHOLAR
  30. Fernández, M. A, Heras, D. L, B, García, M. D, Sáenz, M. T, & Villar, A. (2001). New insights into the mechanism of action of the anti-inflammatory triterpene lupeol. The Journal of Pharmacy and Pharmacology, 53(11), 1533–1539. https://doi.org/10.1211/0022357011777909CrossrefGOOGLE SCHOLAR
  31. Ferraz, C. R, Carvalho, T. T, Manchope, M. F, Artero, N. A, Rasquel-Oliveira, F. S, Fattori, V, Casagrande, R, & Verri, W. A. (2020). Therapeutic potential of flavonoids in pain and inflammation: Mechanisms of action, pre-clinical and clinical data and pharmaceutical development. Molecules, 25(3), 762. https://doi.org/10.3390/molecules25030762CrossrefGOOGLE SCHOLAR
  32. Ferrero-Miliani, L, Nielsen, O. H, Andersen, P. S, & Girardin, S. E. (2007). Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clinical and Experimental Immunology, 147(2), 227–235. https://doi.org/10.1111/j.1365-2249.2006.03261.xCrossrefGOOGLE SCHOLAR
  33. Ganeshpurkar, A, & Saluja, A. K. (2017). The pharmacological potential of rutin. Saudi Pharmaceutical Journal, 25(2), 149–164. https://doi.org/10.1016/j.jsps.2016.04.025CrossrefGOOGLE SCHOLAR
  34. Garg, S, Malhotra, R. K, Khan, S. I, Sarkar, S, Susrutha, P. N, Singh, V, Goyal, S, Nag, T. C, Ray, R, Bhatia, J, & Arya, D. S. (2019). Fisetin attenuates isoproterenol-induced cardiac ischemic injury in vivo by suppressing RAGE/NF-κB mediated oxidative stress, apoptosis and inflammation. Phytomedicine, 56, 147–155. https://doi.org/10.1016/j.phymed.2018.09.187CrossrefGOOGLE SCHOLAR
  35. Ghante, M. H, & Jamkhande, P. G. (2019). Role of pentacyclic triterpenoids in chemoprevention and anticancer treatment: An overview on targets and underling mechanisms. Journal of Pharmacopuncture, 22(2), 55–67. https://doi.org/10.3831/KPI.201.22.007CrossrefGOOGLE SCHOLAR
  36. Ghasemian, M, Owlia, S, & Owlia, M. B. (2016). Review of anti-inflammatory herbal medicines. Advances in Pharmacological Sciences. https://doi.org/10.1155/2016/9130979CrossrefGOOGLE SCHOLAR
  37. Grynkiewicz, G, & Demchuk, O. M. (2019). New perspectives for fisetin. Frontiers in Chemistry, 7, 697. https://doi.org/10.3389/fchem.2019.00697CrossrefGOOGLE SCHOLAR
  38. Guan, F, Wang, Q, Bao, Y, & Chao, Y. (2021). Anti-rheumatic effect of quercetin and recent developments in nano formulation. RSC Advances, 11(13), 7280–7293. https://doi.org/10.1039/d0ra08817jCrossrefGOOGLE SCHOLAR
  39. Han, S, Wu, H, Li, W, & Gao, P. (2015). Protective effects of genistein in homocysteine-induced endothelial cell inflammatory injury. Molecular and Cellular Biochemistry, 403(1–2), 43–49. https://doi.org/10.1007/s11010-015-2335-0CrossrefGOOGLE SCHOLAR
  40. Huang, L, Guan, T, Qian, Y, Huang, M, Tang, X, Li, Y, & Sun, H. (2011). Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B. European Journal of Pharmacology, 672(1–3), 169–174. https://doi.org/10.1016/j.ejphar.2011.09.175CrossrefGOOGLE SCHOLAR
  41. Imperiale, J. C, Schlachet, I, Lewicki, M, Sosnik, A, & Biglione, M. M. (2019). Oral pharmacokinetics of a chitosan-based nano- Drug delivery system of interferon alpha. Polymers, 11(11), 1862. https://doi.org/10.3390/polym11111862CrossrefGOOGLE SCHOLAR
  42. Indra, M. R, Karyono, S, Ratnawati, R, & Malik, S. G. (2013). Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in leptin-induced human umbilical vein endothelial cells (HUVECs). BMC Research Notes, 6, 275. https://doi.org/10.1186/1756-0500-6-275CrossrefGOOGLE SCHOLAR
  43. Jäger, S, Trojan, H, Kopp, T, Laszczyk, M. N, & Scheffler, A. (2009). Pentacyclic triterpene distribution in various plants – Rich sources for a new group of multi-potent plant extracts. Molecules, 14(6), 2016–2031. https://doi.org/10.3390/molecules14062016CrossrefGOOGLE SCHOLAR
  44. Jamtsho, T, Loukas, A, & Wangchuk, P. (2024). Pharmaceutical potential of remedial plants and helminths for treating inflammatory bowel disease. Pharmaceuticals, 17(7), 819. https://doi.org/10.3390/ph17070819CrossrefGOOGLE SCHOLAR
  45. Jannat, K, & Paul, A. (2021). K, Bondhon, T. A, Hasan, A, Nawaz, M, Jahan, R, Mahboob, T, Nissapatorn, V, Wilairatana, P, Pereira, M. L, Rahmatullah, M. Nanotechnology Applications of Flavonoids for Viral Diseases. Pharmaceutics, 13(11), 1895. https://doi.org/10.3390/pharmaceutics13111895CrossrefGOOGLE SCHOLAR
  46. Jeong, W, Hong, S. S, Kim, N, Yang, Y. T, Shin, Y. S, Lee, C, Hwang, B. Y, & Lee, D. (2009). Bioactive triterpenoids from callistemon lanceolatus. Archives of Pharmacal Research, 32(6), 845–849. https://doi.org/10.1007/s12272-009-1605-3CrossrefGOOGLE SCHOLAR
  47. Jubilee, R, Komala, M, & Patel, S. (2024). Therapeutic potential of resveratrol and lignans in the management of tuberculosis. Cell Biochemistry and Biophysics, 82(3), 1809–1823. https://doi.org/10.1007/s12013-024-01378-7CrossrefGOOGLE SCHOLAR
  48. Juthani, V. V, Clearfield, E, & Chuck, R. S. (2017). Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. The Cochrane Database of Systematic Reviews, 7(7), Article CD010516. https://doi.org/10.1002/14651858.CD010516.pub2CrossrefGOOGLE SCHOLAR
  49. Kahraman, E, Güngör, S, & Özsoy, Y. (2017). Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery. Therapeutic Delivery, 8(11), 967–985. https://doi.org/10.4155/tde-2017-0075CrossrefGOOGLE SCHOLAR
  50. Kamble, S. M, Patel, H. M, Goyal, S. N, Noolvi, M. N, Mahajan, U. B, Ojha, S, & Patil, C. R. (2017). In silico evidence for binding of pentacyclic triterpenoids to Keap1-Nrf2 protein–protein binding site. Combinatorial Chemistry and High Throughput Screening, 20(3), 215–234. https://doi.org/10.2174/1386207319666161214111822CrossrefGOOGLE SCHOLAR
  51. Kaps, A, Gwiazdoń, P, & Chodurek, E. (2021). Nanoformulations for delivery of pentacyclic triterpenoids in anticancer therapies. Molecules, 26(6), 1764. https://doi.org/10.3390/molecules26061764CrossrefGOOGLE SCHOLAR
  52. Kashyap, D, Sharma, A, Tuli, H. S, Punia, S, & Sharma, A. K. (2016). Ur solic acid and oleanolic acid: Pentacyclic terpenoids with promising anti-inflammatory activities. Recent Patents on Inflammation and Allergy Drug Discovery, 10(1), 21–33. https://doi.org/10.2174/1872213x10666160711143904CrossrefGOOGLE SCHOLAR
  53. Khan, I, Kant, C, Sanwaria, A, & Meena, L. (2010). Acute cardiac toxicity of nerium oleander/indicum poisoning (kaner) poisoning. Heart Views, 11(3), 115–116. https://doi.org/10.4103/1995-705X.76803CrossrefGOOGLE SCHOLAR
  54. Kim, D, Han, K, Chung, I, Kim, D, Kim, S, Kwon, B, Jeong, T, Park, M, Ahn, E, & Baek, N. (2005). Triterpenoids from the flower of campsis grandiflora K. Schum. As Human Acyl-coa: Cholesterol Acyltransferase Inhibitors. Archives of Pharmacal Research, 28(5), 550–556. https://doi.org/10.1007/BF02977757CrossrefGOOGLE SCHOLAR
  55. Kumari, A, Kumar, V, & Yadav, S. K. (2012). Plant extract synthesized PLA nanoparticles for controlled and sustained release of quercetin: A green approach. PLOS One, 7(7), Article E41230. https://doi.org/10.1371/journal.pone.0041230CrossrefGOOGLE SCHOLAR
  56. Kwak, J, Seo, J. M, Kim, N, Arasu, M. V, Kim, S, Yoon, M. K, & Kim, S. (2017). Variation of quercetin glycoside derivatives in three onion (allium cepa L.) Varieties. Saudi Journal of Biological Sciences, 24(6), 1387–1391. https://doi.org/10.1016/j.sjbs.2016.05.014CrossrefGOOGLE SCHOLAR
  57. L, A, Kumar, K, J, & Shanmugam, R. (2024). Formulation of quercetin mouthwash and anti-microbial potential against critical pathogens: An in vitro evaluation. Cureus, 16(1), Article E51688. https://doi.org/10.7759/cureus.51688CrossrefGOOGLE SCHOLAR
  58. Lee, W, Ku, S, & Bae, J. (2012). Barrier protective effects of rutin in LPS-induced inflammation in vitro and in vivo. Food and Chemical Toxicology, 50(9), 3048–3055. https://doi.org/10.1016/j.fct.2012.06.013CrossrefGOOGLE SCHOLAR
  59. Lee, W, Yang, E, Ku, S, Song, K, & Bae, J. (2013). Anti-inflammatory effects of oleanolic acid on LPS-induced inflammation in vitro and in vivo. Inflammation, 36(1), 94–102. https://doi.org/10.1007/s10753-012-9523-9CrossrefGOOGLE SCHOLAR
  60. Li, H, Zhao, X, Ma, Y, Zhai, G, Li, L, & Lou, H. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release, 133(3), 238–244. https://doi.org/10.1016/j.jconrel.2008.10.002CrossrefGOOGLE SCHOLAR
  61. Li, Y, Yao, J, Han, C, Yang, J, Chaudhry, M. T, Wang, S, Liu, H, & Yin, Y. (2016). Quercetin, inflammation and immunity. Nutrients, 8(3), 167. https://doi.org/10.3390/nu8030167CrossrefGOOGLE SCHOLAR
  62. Lin, A, Lin, C, Du, Y, Lübken, T, Chiang, M. Y, Chen, I, Wu, C, Hwang, T, Chen, S, Yen, M, Chang, F, & Wu, Y. (2009). Acasiane A and B and farnesirane A and B, diterpene derivatives from the roots of acacia farnesiana. Planta Medica, 75(3), 256–261. [EPub]. https://doi.org/10.1055/s-0028-1112201CrossrefGOOGLE SCHOLAR
  63. Lin, C, Tseng, C, Chen, K, Wu, S, Liaw, C, & Lee, J. (2015). Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- And MAPK-ERK1/2-mediated COX-2 expression. British Journal of Pharmacology, 172(18), 4481–4492. https://doi.org/10.1111/bph.13233CrossrefGOOGLE SCHOLAR
  64. Lozano-Mena, G, Sánchez-González, M, Juan, M. E, & Planas, J. M. (2014). Maslinic acid, a natural phytoalexin-type triterpene from olives-A promising nutraceutical? Molecules, 19(8), 11538-11559. https://doi.org/10.3390/molecules190811538CrossrefGOOGLE SCHOLAR
  65. Lu, H, Xi, C, Chen, J, & Li, W. (2009). [Determination of triterpenoid acids in leaves of eriobotrya japonica collected at in different seasons]. Zhongguo Zhong Yao Za Zhi, 34(18), 2353–2355.GOOGLE SCHOLAR
  66. Lucetti, D. L, Lucetti, E. C, Bandeira, M. A. M, Veras, H. N, Silva, A. H, Leal, L. K. A, Lopes, A. A, Alves, V. C, Silva, G. S, Brito, G. A, & Viana, G. B. (2010). Anti-inflammatory effects and possible mechanism of action of lupeol acetate isolated from himatanthus drasticus (Mart.). Plumel. Journal of Inflammation, 7, 60. https://doi.org/10.1186/1476-9255-7-60CrossrefGOOGLE SCHOLAR
  67. Lv, L, Lv, L, Zhang, Y, & Kong, Q. (2011). Luteolin prevents LPS-induced TNF-α expression in cardiac myocytes through inhibiting NF-κB signaling pathway. Inflammation, 34(6), 620–629. https://doi.org/10.1007/s10753-010-9271-7CrossrefGOOGLE SCHOLAR
  68. Maio, A, Pibiri, I, Morreale, M, Mantia, F. P. L, & Scaffaro, R. (2021). An overview of functionalized graphene nanomaterials for advanced applications. Nanomaterials, 11(7), 1717. https://doi.org/10.3390/nano11071717CrossrefGOOGLE SCHOLAR
  69. Medzhitov, R. (2010). Inflammation 2010: New adventures of an old flame. Cell, 140(6), 771–776. https://doi.org/10.1016/j.cell.2010.03.006CrossrefGOOGLE SCHOLAR
  70. Meeran, N, M, F, Goyal, S. N, Suchal, K, Sharma, C, Patil, C. R, & Ojha, S. K. (2018). Pharmacological properties, molecular mechanisms and pharmaceutical development of asiatic acid: A pentacyclic triterpenoid of therapeutic promise. Frontiers in Pharmacology, 9, 892. https://doi.org/10.3389/fphar.2018.00892CrossrefGOOGLE SCHOLAR
  71. Mioc, M, Pavel, I. Z, Ghiulai, R, Coricovac, D. E, Farcaş, C, Mihali, C, Oprean, C, Serafim, V, Popovici, R. A, Dehelean, C. A, Shtilman, M. I, Tsatsakis, A. M, & Şoica, C. (2018). The cytotoxic effects of betulin-conjugated gold nanoparticles as stable formulations in normal and melanoma cells. Frontiers in Pharmacology, 9, 429. https://doi.org/10.3389/fphar.2018.00429CrossrefGOOGLE SCHOLAR
  72. Mirza, M. A, Mahmood, S, Hilles, A. R, Ali, A, Khan, M. Z, Zaidi, S. A. A, Iqbal, Z, & Ge, Y. (2023). Quercetin as a therapeutic product: Evaluation of its pharmacological action and clinical applications-A review. Pharmaceuticals, 16(11), 1631. https://doi.org/10.3390/ph16111631CrossrefGOOGLE SCHOLAR
  73. Mishra, V, Bansal, K. K, Verma, A, Yadav, N, Thakur, S, Sudhakar, K, & Rosenholm, J. M. (2018). Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics, 10(4), 191. https://doi.org/10.3390/pharmaceutics10040191CrossrefGOOGLE SCHOLAR
  74. Moskovtchenko, J. F, & Cognet, J. B. (1976). Classification des corticoïdes [Classification of corticoids]. Annales de L’anesthesiologie Française, 17(4), 399–405.GOOGLE SCHOLAR
  75. Muruganathan, N, Dhanapal, A. R, Baskar, V, Muthuramalingam, P, Selvaraj, D, Aara, H, Abdullah, S, M, Z, & Sivanesan, I. (2022). Recent updates on source, biosynthesis and therapeutic potential of natural flavonoid luteolin: A review. Metabolites, 12(11), 1145. https://doi.org/10.3390/metabo12111145CrossrefGOOGLE SCHOLAR
  76. Nathan, C, & Ding, A. (2010). Nonresolving inflammation. Cell, 140(6), 871–882. https://doi.org/10.1016/j.cell.2010.02.029CrossrefGOOGLE SCHOLAR
  77. Nie, X, Chen, Z, Pang, L, Wang, L, Jiang, H, Chen, Y, Zhang, Z, Fu, C, Ren, B, & Zhang, J. (2020). Oral nano drug delivery systems for the treatment of type 2 diabetes mellitus: An available administration strategy for antidiabetic phytocompounds. International Journal of Nanomedicine, 15, 10215–10240. https://doi.org/10.2147/IJN.S285134CrossrefGOOGLE SCHOLAR
  78. Ntalouka, F, & Tsirivakou, A. (2023). Luteolin: A promising natural agent in management of pain in chronic conditions. Frontiers in Pain Research, 4, Article 1114428. https://doi.org/10.3389/fpain.2023.1114428CrossrefGOOGLE SCHOLAR
  79. Ooi, K. X, Poo, C. L, Subramaniam, M, Cordell, G. A, & Lim, Y. M. (2023). Maslinic acid exerts anticancer effects by targeting cancer hallmarks. Phytomedicine, 110, Article 154631. https://doi.org/10.1016/j.phymed.2022.154631CrossrefGOOGLE SCHOLAR
  80. Oyagbemi, A. A, Omobowale, T. O, Ola-Davies, O. E, Asenuga, E. R, Ajibade, T. O, Adejumobi, O. A, Afolabi, J. M, Ogunpolu, B. S, Falayi, O. O, Saba, A. B, Adedapo, A. A, & Yakubu, M. A. (2018). Luteolin-mediated KIM-1/NF-kB/Nrf2 signaling pathways protects sodium fluoride-induced hypertension and cardiovascular complications. Biofactors, 44(6), 518–531. https://doi.org/10.1002/biof.1449CrossrefGOOGLE SCHOLAR
  81. Patil, K. R, Mohapatra, P, Patel, H. M, Goyal, S. N, Ojha, S, Kundu, C. N, & Patil, C. R. (2015). Pentacyclic triterpenoids inhibit IKKβ mediated activation of NF-κB pathway: In silico and in vitro evidences. PLOS One, 10(5), Article E0125709. https://doi.org/10.1371/journal.pone.0125709CrossrefGOOGLE SCHOLAR
  82. Patil, S, & Chandrasekaran, R. (2020). Biogenic nanoparticles: A comprehensive perspective in synthesis, characterization, application and its challenges. Journal, Genetic Engineering & Biotechnology, 18(1), 67. https://doi.org/10.1186/s43141-020-00081-3CrossrefGOOGLE SCHOLAR
  83. Patra, J. (2018). K, Das, G, Fraceto, L. F, Campos, E. V. R, Rodriguez-torres, M. D. P, Acosta-torres, L. S, Diaz-torres, L. A, Grillo, R, Swamy, M. K, Sharma, S, Habtemariam, S, Shin, H. Nano Based Drug Delivery Systems: Recent Developments and Future Prospects. Journal of Nanobiotechnology, 16(1), 71. https://doi.org/10.1186/s12951-018-0392-8CrossrefGOOGLE SCHOLAR
  84. Pollastri, S, & Tattini, M. (2011). Flavonols: Old compounds for old roles. Annals of Botany, 108(7), 1225–1233. https://doi.org/10.1093/aob/mcr234CrossrefGOOGLE SCHOLAR
  85. Puniani, E, Cayer, C, Kent, P, Mullally, M, Sánchez-Vindas, P, Álvarez, P, L, Cal, V, Merali, Z, Arnason, J. T, & Durst, T. (2015). Ethnopharmacology of souroubea sympetala and souroubea gilgii (marcgraviaceae) and identification of betulinic acid as an anxiolytic principle. Phytochemistry, 113, 73–78. https://doi.org/10.1016/j.phytochem.2014.02.017CrossrefGOOGLE SCHOLAR
  86. Rainsford, K. D. (2007). Anti-inflammatory drugs in the 21st century. Sub-cellular Biochemistry, 42, 3–27. https://doi.org/10.1007/1-4020-5688-5_1CrossrefGOOGLE SCHOLAR
  87. Rani, N, Bharti, S, Bhatia, J, Nag, T. C, Ray, R, & Arya, D. S. (2016). Chrysin, a PPAR-γ agonist improves myocardial injury in diabetic rats through inhibiting AGE-RAGE mediated oxidative stress and inflammation. Chemico-biological Interactions, 250, 59–67. https://doi.org/10.1016/j.cbi.2016.03.015CrossrefGOOGLE SCHOLAR
  88. Rauf, A, Imran, M, Patel, S, Muzaffar, R, & Bawazeer, S. S. (2017). Rutin: Exploitation of the flavonol for health and homeostasis. Biomedicine and Pharmacotherapy, 96, 1559–1561. https://doi.org/10.1016/j.biopha.2017.08.136CrossrefGOOGLE SCHOLAR
  89. Rawat, R, Chouhan, R. S, Sadhu, V, & Sharma, M. (2023). Clarithromycin-loaded submicron-sized carriers: Pharmacokinetics and pharmacodynamic evaluation. Materials, 16(9), 3593. https://doi.org/10.3390/ma16093593CrossrefGOOGLE SCHOLAR
  90. Ren, K, Jiang, T, Zhou, H, Liang, Y, & Zhao, G. (2018). Apigenin retards atherogenesis by promoting ABCA1-mediated cholesterol efflux and suppressing inflammation. Cellular Physiology and Biochemistry, 47(5), 2170–2184. https://doi.org/10.1159/000491528CrossrefGOOGLE SCHOLAR
  91. Ricciotti, E, & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 986–1000. https://doi.org/10.1161/ATVBAHA.110.207449CrossrefGOOGLE SCHOLAR
  92. Rizvi, S. Z. H, Shah, F. A, Khan, N, Muhammad, I, Ali, K. H, Ansari, M. M, Din, F. U, Qureshi, O. S, Kim, K, Choe, Y, Kim, J, & Zeb, A. (2019). Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. International Journal of Pharmaceutics, 560, 136–143. https://doi.org/10.1016/j.ijpharm.2019.02.002CrossrefGOOGLE SCHOLAR
  93. Roy, A, Bulut, O, Some, S, Mandal, A. K, & Yilmaz, M. D. (2019). Green synthesis of silver nanoparticles: Biomolecule-nanoparticle organizations targeting antimicrobial activity. RSC Advances, 9(5), 2673–2702. https://doi.org/10.1039/c8ra08982eCrossrefGOOGLE SCHOLAR
  94. Sachs, D, Cunha, F. Q, & Ferreira, S. H. (2004). Peripheral analgesic blockade of hypernociception: Activation of Arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proceedings of the National Academy of Sciences of the United States of America, 101(10), 3680–3685. https://doi.org/10.1073/pnas.0308382101CrossrefGOOGLE SCHOLAR
  95. Saleem, M. (2009). Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Letters, 285(2), 109–115. https://doi.org/10.1016/j.canlet.2009.04.033CrossrefGOOGLE SCHOLAR
  96. Santos, A, Veiga, F, & Figueiras, A. (2019). Dendrimers as pharmaceutical excipients: Synthesis, properties, toxicity and biomedical applications. Materials, 13(1), 65. https://doi.org/10.3390/ma13010065CrossrefGOOGLE SCHOLAR
  97. Satapathy, M. K, Yen, T, Jan, J, Tang, R, Wang, J, Taliyan, R, & Yang, C. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183. https://doi.org/10.3390/pharmaceutics13081183CrossrefGOOGLE SCHOLAR
  98. Serafini, M, Peluso, I, & Raguzzini, A. (2010). Flavonoids as anti-inflammatory agents. The Proceedings of the Nutrition Society, 69(3), 273–278. https://doi.org/10.1017/S002966511000162XCrossrefGOOGLE SCHOLAR
  99. Shabir, I, Pandey, V. K, Dar, A. H, Pandiselvam, R, Manzoor, S, Mir, S. A, Shams, R, Dash, K. K, Fayaz, U, Khan, S. A, Jeevarathinam, G, Zhang, Y, Rusu, A. V, & Trif, M. (2022). Nutritional profile, phytochemical compounds, biological activities and utilisation of onion peel for food applications: A review. Sustainability, 14(19), Article 11958. https://doi.org/10.3390/su141911958CrossrefGOOGLE SCHOLAR
  100. Shaikh, S, Verma, H, Yadav, N, Jauhari, M, & Bullangowda, J. (2012). Applications of steroid in clinical practice: A review. International Scholarly Research Notices.GOOGLE SCHOLAR
  101. Shao, J, Fang, Y, Zhao, R, Chen, F, Yang, M, Jiang, J, Chen, Z, Yuan, X, & Jia, L. (2020). Evolution from small molecule to nano-drug delivery systems: An emerging approach for cancer therapy of ursolic acid. Asian Journal of Pharmaceutical Sciences, 15(6), 685–700. https://doi.org/10.1016/j.ajps.2020.03.001CrossrefGOOGLE SCHOLAR
  102. Sharma, M, Sharma, S, & Wadhwa, J. (2019). Improved uptake and therapeutic intervention of curcumin via designing binary lipid nanoparticulate formulation for oral delivery in inflammatory bowel disorder. Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 45–55. https://doi.org/10.1080/21691401.2018.1543191CrossrefGOOGLE SCHOLAR
  103. Suchal, K, Malik, S, Gamad, N, Malhotra, R. K, Goyal, S. N, Chaudhary, U, Bhatia, J, Ojha, S, & Arya, D. S. (2016). Kaempferol attenuates myocardial ischemic injury via inhibition of MAPK signaling pathway in experimental model of myocardial ischemia-reperfusion injury. Oxidative Medicine and Cellular Longevity, Article 4530278. https://doi.org/10.1155/2016/7580731CrossrefGOOGLE SCHOLAR
  104. Sysak, S, Czarczynska-Goslinska, B, Szyk, P, Koczorowski, T, Mlynarczyk, D. T, Szczolko, W, Lesyk, R, & Goslinski, T. (2023). Metal nanoparticle-flavonoid connections: Synthesis, physicochemical and biological properties, as well as potential applications in medicine. Nanomaterials, 13(9), 1531. https://doi.org/10.3390/nano13091531CrossrefGOOGLE SCHOLAR
  105. Szakiel, A, Pączkowski, C, Pensec, F, & Bertsch, C. (2012). Fruit cuticular waxes as a source of biologically active triterpenoids. Phytochemistry Reviews: Proceedings of the Phytochemical Society of Europe, 11(2–3), 263–284. https://doi.org/10.1007/s11101-012-9241-9CrossrefGOOGLE SCHOLAR
  106. Takeuchi, O, & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 140(6), 805–820. https://doi.org/10.1016/j.cell.2010.01.022CrossrefGOOGLE SCHOLAR
  107. Tang, X, Liu, J, Dong, W, Li, P, Li, L, Zheng, Y, & Hou, J. (2014). [Intervention effect of quercetin on inflammatory secretion of cardiac fibroblasts]. Zhongguo Zhong Yao Za Zhi, 39(12), 2314–2317.GOOGLE SCHOLAR
  108. Vasconcelos, J. F, Teixeira, M. M, Barbosa-Filho, J. M, Lúcio, A. S, Almeida, J. R, Queiroz, D, L, P, Ribeiro-Dos-Santos, R, & Soares, M. B. (2008). The triterpenoid lupeol attenuates allergic airway inflammation in a murine model. International Immunopharmacology, 8(9), 1216–1221. [EPub]. https://doi.org/10.1016/j.intimp.2008.04.011CrossrefGOOGLE SCHOLAR
  109. Viscusi, G, Paolella, G, Lamberti, E, Caputo, I, & Gorrasi, G. (2023). Quercetin-loaded polycaprolactone-polyvinylpyrrolidone electrospun membranes for health application: Design, characterization, modeling and cytotoxicity studies. Membranes, 13(2), 242. https://doi.org/10.3390/membranes13020242CrossrefGOOGLE SCHOLAR
  110. Vyas, N, & Argal, A. (2014). Isolation and characterization of oleanolic acid from roots of lantana camara. Asian Journal of Pharmaceutical and Clinical Research, 7(7), 189–191. https://journals.innovareacademics.in/index.php/ajpcr/article/view/1116GOOGLE SCHOLAR
  111. Wang, L, Yin, Q, Liu, C, Tang, Y, Sun, C, & Zhuang, J. (2021). Nanoformulations of ursolic acid: A modern natural anticancer molecule. Frontiers in Pharmacology, 12, Article 706121. https://doi.org/10.3389/fphar.2021.706121CrossrefGOOGLE SCHOLAR
  112. Wang, S, Su, R, Nie, S, Sun, M, Zhang, J, Wu, D, & Moustaid-Moussa, N. (2014). Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. The Journal of Nutritional Biochemistry, 25(4), 363–376. https://doi.org/10.1016/j.jnutbio.2013.10.002CrossrefGOOGLE SCHOLAR
  113. Woźniak, Skąpska, S, & Marszałek, K. (2015). Ursolic acid-A pentacyclic triterpenoid with a wide spectrum of pharmacological activities. Molecules, 20(11), 20614–20641. https://doi.org/10.3390/molecules201119721CrossrefGOOGLE SCHOLAR
  114. Xia, E, Wang, B, Xu, X, Zhu, L, Song, Y, & Li, H. (2011). Microwave-assisted extraction of oleanolic acid and ursolic acid from ligustrum lucidum ait. International Journal of Molecular Sciences, 12(8), 5319–5329. https://doi.org/10.3390/ijms12085319CrossrefGOOGLE SCHOLAR
  115. Xia, X, Liu, H, Lv, H, Zhang, J, Zhou, J, & Zhao, Z. (2017). Preparation, characterization and in vitro/vivo studies of oleanolic acid-loaded lactoferrin nanoparticles. Drug Design, Development and Therapy, 11, 1417–1427. https://doi.org/10.2147/DDDT.S133997CrossrefGOOGLE SCHOLAR
  116. Xiong, D, Hu, W, Ye, S, & Tan, Y. (2018). Isoliquiritigenin alleviated the ang II-induced hypertensive renal injury through suppressing inflammation cytokines and oxidative stress-induced apoptosis via Nrf2 and NF-κB pathways. Biochemical and Biophysical Research Communications, 506(1), 161–168. https://doi.org/10.1016/j.bbrc.2018.09.013CrossrefGOOGLE SCHOLAR
  117. Yadav, D. Y, Suri, S, Choudhary, A, Sikender, M, Hemant, H, Beg, M. N, Garg, V, Ahmad, A, & Asif, M. (2011). Novel approach: Herbal remedies and natural products in pharmaceutical science as nano drug delivery systems.GOOGLE SCHOLAR
  118. Yamashita, K, Lu, H, Lu, J, Chen, G, Yokoyama, T, Sagara, Y, Manabe, M, & Kodama, H. (2002). Effect of three triterpenoids, lupeol, betulin and betulinic acid on the stimulus-induced superoxide generation and tyrosyl phosphorylation of proteins in human neutrophils. Clinica Chimica Acta; International Journal of Clinical Chemistry, 325(1–2), 91–96. )00252-8. https://doi.org/10.1016/s0009-8981(02CrossrefGOOGLE SCHOLAR
  119. Yang, C, Guo, Y, Huang, T, Zhao, J, Huang, X, Tang, H, An, N, Pan, Q, Xu, Y, & Liu, H. (2018). Asiatic acid protects against cisplatin-induced acute kidney injury via anti-apoptosis and anti-inflammation. Biomedicine and Pharmacotherapy, 107, 1354–1362. https://doi.org/10.1016/j.biopha.2018.08.126CrossrefGOOGLE SCHOLAR
  120. Yang, E, Lee, W, Ku, S, Song, K, & Bae, J. (2012). Anti-inflammatory activities of oleanolic acid on HMGB1 activated HUVECs. Food and Chemical Toxicology, 50(5), 1288–1294. https://doi.org/10.1016/j.fct.2012.02.026CrossrefGOOGLE SCHOLAR
  121. Yatoo, M. I, Gopalakrishnan, A, Saxena, A, Parray, O. R, Tufani, N. A, Chakraborty, S, Tiwari, R, Dhama, K, & Iqbal, H. M. N. (2018). Anti-inflammatory drugs and herbs with special emphasis on herbal medicines for countering inflammatory diseases and disorders – A review. Recent Patents on Inflammation and Allergy Drug Discovery, 12(1), 39–58. https://doi.org/10.2174/1872213X12666180115153635CrossrefGOOGLE SCHOLAR
  122. Yetisgin, A. A, Cetinel, S, Zuvin, M, Kosar, A, & Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. Molecules, 25(9), 2193. https://doi.org/10.3390/molecules25092193CrossrefGOOGLE SCHOLAR
  123. Yu, D, Kan, Z, Shan, F, Zang, J, & Zhou, J. (2020). Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes. Molecular Pharmaceutics, 17(12), 4443–4462. https://doi.org/10.1021/acs.molpharmaceut.0c00443CrossrefGOOGLE SCHOLAR
  124. Yu, Y, Miyashiro, H, Nakamura, N, Hattori, M, & Park, J. C. (2007). Effects of triterpenoids and flavonoids isolated from alnus firma on HIV-1 viral enzymes. Archives of Pharmacal Research, 30(7), 820–826. https://doi.org/10.1007/BF02978831CrossrefGOOGLE SCHOLAR
  125. Yun, Y, Han, S, Park, E, Yim, D, Lee, S, Lee, C, Cho, K, & Kim, K. (2003). Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. Archives of Pharmacal Research, 26(12), 1087–1095. https://doi.org/10.1007/BF02994763CrossrefGOOGLE SCHOLAR
  126. Zhai, J, Dong, X, Yan, F, Guo, H, & Yang, J. (2022). Oleandrin: A systematic review of its natural sources, structural properties, detection methods, pharmacokinetics and toxicology. Frontiers in Pharmacology, 13, Article 822726. https://doi.org/10.3389/fphar.2022.822726CrossrefGOOGLE SCHOLAR
  127. Zhao, M, Wu, F, Tang, Z, Yang, X, Liu, Y, Wang, F, & Chen, B. (2023). Anti-inflammatory and antioxidant activity of ursolic acid: A systematic review and meta-analysis. Frontiers in Pharmacology, 14, Article 1256946. https://doi.org/10.3389/fphar.2023.1256946CrossrefGOOGLE SCHOLAR
  128. Zhou, Y, Hong, Y, & Huang, H. (2016). Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-κB signaling pathway. Kidney and Blood Pressure Research, 41(6), 901–910. https://doi.org/10.1159/000452591CrossrefGOOGLE SCHOLAR
  129. Zúñiga, L, & M (2021). Á, Moreno-Moral, A, Ocaña-Granados, A, Padilla-Moreno, F. A, Castillo-fernández, A. M, Guillamón-fernández, D, Ramírez-sánchez, C, Sanchez-palop, M, Martínez-colmenero, J, Pimentel-villar, M. A, Blázquez-roselló, S, Moreno-sánchez, J. J, López-vílchez, M, Prior-sánchez, I, Jódar-moreno, R, López Ruz, M. Á. High-dose Corticosteroid Pulse Therapy Increases the Survival Rate in COVID-19 Patients At Risk of Hyper-inflammatory Response. PLOS One, 16(1), Article E0243964. https://doi.org/10.1371/journal.pone.0243964CrossrefGOOGLE SCHOLAR

Cite this article

SELECT FORMAT

Ravikumar, L., Velmurugan, R., Jahnavi, P., Vidiyala, P., Kumar, J. P., Rahul, A., & Bhuvaneshwaran, P. (2025). Nanoscale Formulations for Targeted Drug Delivery: Enhancing Stability, Release Control and Therapeutic Efficacy. International Journal of Pharmaceutical Investigation, 15(3), 837-848. https://doi.org/10.5530/ijpi.20250189

Copyright and licence

© 2025 Author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0